Management of brain metastasis from rectal cancer using whole‑brain radiation therapy followed by bevacizumab and chemotherapy: A case report.
bevacizumab
brain metastasis
case report
rectal cancer
whole-brain radiation therapy
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
07
02
2023
accepted:
17
07
2023
medline:
18
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Brain metastases in colorectal cancer are uncommon, which has resulted in a shortage of data concerning their screening and management. Multiple therapeutic modalities with chemotherapy, chemoradiation and targeted therapy, including bevacizumab and cetuximab regimens, have shown promising results. The present study describes the case of a 47-year-old male, diagnosed with T4N2M1 rectal cancer who underwent systemic therapy with modified FOLFOXIRI and cetuximab. The patient achieved a complete clinical response after 12 cycles. Following the discontinuation of cetuximab, the patient was given capecitabine as a maintenance therapy and subsequently developed brain metastasis. The patient received whole-brain radiation therapy (WBRT) followed by a bevacizumab plus FOLFIRI regimen. The patient showed a good response as revealed by cranial magnetic resonance imaging, with a reduction in lesion size and no sign of cerebral edema. In addition, the patient maintained a stable neurological condition for >10 months. These findings suggest that the early detection of brain metastases requires the close monitoring of neurological symptoms. In addition, WBRT followed by bevacizumab and chemotherapy is a potential management plan for brain metastasis from rectal cancer.
Identifiants
pubmed: 37720667
doi: 10.3892/ol.2023.14033
pii: OL-26-4-14033
pmc: PMC10502923
doi:
Types de publication
Case Reports
Langues
eng
Pagination
446Informations de copyright
Copyright © 2023, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Clin Oncol. 2022 Feb 10;40(5):492-516
pubmed: 34932393
Sci Rep. 2019 Nov 28;9(1):17792
pubmed: 31780762
Clin Colorectal Cancer. 2020 Dec;19(4):263-269
pubmed: 33012679
Curr Oncol. 2012 Oct;19(5):254-8
pubmed: 23144573
Sci Rep. 2020 Mar 9;10(1):4340
pubmed: 32152433
J Gastrointest Cancer. 2016 Mar;47(1):82-8
pubmed: 26714801
Tumori. 2019 Oct;105(5):427-433
pubmed: 29714653
Br J Cancer. 2021 Feb;124(3):587-594
pubmed: 33154570
Int J Colorectal Dis. 2022 Feb;37(2):337-348
pubmed: 34767074
J Clin Oncol. 2007 May 1;25(13):1670-6
pubmed: 17470860
ESMO Open. 2023 Jun;8(3):101558
pubmed: 37236086
Expert Opin Drug Deliv. 2013 Jul;10(7):907-26
pubmed: 23751126
Medicine (Baltimore). 2022 Oct 7;101(40):e30273
pubmed: 36221357
Cancers (Basel). 2021 Feb 21;13(4):
pubmed: 33669974
Sci Rep. 2016 Jul 15;6:29765
pubmed: 27416752
Front Pharmacol. 2021 May 28;12:632076
pubmed: 34122063
Neurooncol Adv. 2020 Mar 16;2(1):vdaa038
pubmed: 32642693
BMC Cancer. 2019 Jul 31;19(1):755
pubmed: 31366387
J Natl Compr Canc Netw. 2022 Oct;20(10):1139-1167
pubmed: 36240850
Ann Oncol. 2016 Jun;27(6):1074-1081
pubmed: 26940686
Dis Colon Rectum. 1999 Nov;42(11):1467-71
pubmed: 10566536